Filing Flows › Lipocine (LPCN) › Q3 2026 › vs Q3 2025
Lipocine (LPCN) Q3 2026 vs Q3 2025 (year over year)
Lipocine's revenue rose $2.2M (20×) from $115K in Q3 2025 to $2.3M in Q3 2026.
Lipocine, Q3 2026: revenue $2.3M (20× year over year), operating margin -37.9%, net loss $666K, operating cash flow −$1.8M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $2.3M | $115K | $2.2M | 20× |
| Other income, net | $202K | $174K | $28K | +16% |
| Net loss | $666K | $3.2M | −$2.5M | -79% |
| Costs & expenses | $3.2M | $3.5M | −$317K | -9% |
| Operating costs | $3.2M | $3.5M | −$317K | -9% |
| Research & development | $2.1M | $2.7M | −$638K | -24% |
| General & admin | $1.1M | $768K | $321K | +42% |
| Operating cash sources | $1.9M | $3.1M | −$1.2M | -38% |
| Depreciation & amortization | $15K | $14K | $1K | +4% |
| Share-based compensation | $74K | $53K | $21K | +39% |
| Cash used in operations | $1.8M | $3.0M | −$1.2M | -39% |
| Net loss absorbed | $666K | $3.2M | −$2.5M | -79% |
| Working capital & other | $1.2M | −$134K | $1.4M | — |
Questions
How much did Lipocine's revenue grow year over year in Q3 2026?
Lipocine's revenue rose $2.2M (20×) from $115K in Q3 2025 to $2.3M in Q3 2026.